Several biotechnology and pharmaceutical companies posted notable gains in Thursday's after-hours trading session, driven by corporate updates, clinical milestones, and acquisition speculation.China SXT Pharmaceuticals, Inc. (SXTC) climbed 13.6% to $1.42, adding $0.17 after announcing the launch of its Strategic Artificial Intelligence (AI) Insights Initiative. The program is designed to integrate AI-driven analytics into product portfolio planning and market intelligence, reinforcing the company's long-te ...

专注癌症药物研发的生物科技公司Revolution Medicines(RVMD.US)夜盘涨超13%，报121.5美元。消息 面上，据英国《金融时报》引述知情人士称，默沙东正就收购Revolution Medicines进行磋商。报道称， 交易作价或介乎280亿至320亿美元，若最终落实，将成为自2023年底辉瑞以430亿美元收购Seagen以 来，规模最大的药业并购之一。此前艾伯维否认正在洽谈收购Revolution Medicines。 ...

智通财经APP获悉，据报道，默沙东(MRK.US)正在洽谈收购专注于癌症领域的生物技术公司 Revolution Medicines(RVMD.US)。该报道援引知情人士消息称，双方讨论的交易价格在280亿美元至 320亿美元之间。若交易达成，这将成为自2023年底辉瑞(PFE.US)以430亿美元收购Seagen以来规模最大 的制药行业交易之一。受此消息提振，截至发稿，Revolution Medicines周四美股盘后大涨超15%。 根据行业研究的数据，在Daraxonrasib的带动下，到2035年，胰腺癌治疗药物市场的规模可能会扩大十 倍，达到30亿美元以上。去年10月，美国食品药品监督管理局(FDA)选择Daraxonrasib参加了一项旨在 帮助有前景的药物加速获批的新凭单计划。行业研究称，Daraxonrasib预计最快将在2026年获批上市。 通常情况下，每年1月制药公司之间的并购交易会明显升温，因为生命科学行业的企业会齐聚旧金山， 参加一年一度的摩根大通医疗健康大会(JPMorgan Healthcare Conference)——该会议被视为并购交易的 温床。根据行业研究的分析，Revol ...

| 厨局: 112.43 | JS | | --- | --- | | 最低: 94.52 | Bf | | 52周最高: 112.43 | 트 | | 52周最低: 29.17 | में मे | | 每股收益: -4.97 | 服 | | 每股净资产: 8.42 | 服 | | 机构持股: -- | B | 1月9日， Financial T imes 报道默沙 东正在与Revolution Medicines（ RVMD ）讨论收购事宜， 价 格范围为280亿美元~320亿美元。 R VMD美股盘后大涨17.24%，市值达到约243亿 美元。然而就在两 天前谣传艾伯维要收购RVMD，后者股价也暴涨，后艾伯维予以否认。 这表明制药行业正在进行战略扩张。默沙东的财务状况稳健，盈利能力强大，资产负债表 稳健。估值指标显示，默沙东的估值合理，市场情绪稳定。RVMD的RAS抑制剂组合资产 预计销售峰值超1 0 0亿美元。 | COMPOUND | FOCUS | STUDY DETAILS | | EARLY CLINICAL DEVELOPMENT | REGISTRATIONAL TRIAL | | --- ...

Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter. ...

Erasca Inc. (NASDAQ:ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. • Erasca shares are advancing steadily. Why is ERAS stock trading higher?The movement came in reaction to a rumored deal, wherein AbbVie Inc. (NYSE:ABBV) was reportedly in advanced talks to buy cancer-drug biotech Revolution Medicines, Inc. (NASDAQ:RVMD) .The Wall Street Journal report on Wednesday noted Revolution had drawn interest from other bidders, citing people familiar with the mat ...

Key Takeaways RVMD stock surged nearly 29% after a WSJ report cited possible AbbVie acquisition interest.ABBV later denied takeover talks, though the report said a deal could value RVMD at $20B or more.Revolution Medicines develops RAS(ON) cancer drugs, with lead candidate daraxonrasib in late-stage studies.Shares of Revolution Medicines (RVMD) rose nearly 29% on Wednesday following a report issued by the Wall Street Journal (WSJ), as cited in a Yahoo Finance article, which stated that pharma giant AbbVie ( ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapyFirst Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLCRevolution Medicines’ third RAS(ON) inhibitor to receive this designation REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWS ...

美国癌症药物开发商Revolution Medicines(RVMD.US)盘前跌9%，报93.47美元。消息面上，艾伯维否认 正在洽谈收购Revolution Medicines，此前华尔街日报曾报道艾伯维正在就收购Revolution进行深入讨 论，后者的估值可能在200亿美元或更高。Revolution Medicines则表示，根据公司政策，不会对谣言或 猜测发表评论。(格隆汇) ...

Shares of Revolution Medicines Inc. (NASDAQ:RVMD) tumbled in after-hours trading on Wednesday after AbbVie Inc. (NYSE:ABBV) denied reports that it was in talks to acquire the cancer-drug developer, reversing an over 28% rally sparked by the takeover speculation.Report Lifts AbbVie Stock Too As Investors Cheer Oncology ProspectsThe Wall Street Journal reported on Wednesday that AbbVie was in advanced talks to buy Revolution Medicines, but the terms and a potential purchase price were not disclosed. Revolutio ...